Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

• Revenue in USD (TTM)0.00
• Net income in USD-42.55m
• Incorporated2018
• Employees56.00

• Location
  Pulse Biosciences Inc3957 Point Eden WayHAYWARD 94545-3720United StatesUSA
• Phone+1 (510) 906-4600
• Fax+1 (302) 655-5049
• Websitehttps://www.pulsebiosciences.com/